nodes	percent_of_prediction	percent_of_DWPC	metapath
Sumatriptan—SLCO1A2—Rosuvastatin—atherosclerosis	0.0658	0.0876	CbGbCtD
Sumatriptan—SLCO1B1—Ezetimibe—atherosclerosis	0.0621	0.0826	CbGbCtD
Sumatriptan—SLCO1B1—Rosuvastatin—atherosclerosis	0.0621	0.0826	CbGbCtD
Sumatriptan—SLCO1A2—Simvastatin—atherosclerosis	0.0612	0.0814	CbGbCtD
Sumatriptan—SLCO1A2—Pravastatin—atherosclerosis	0.0599	0.0797	CbGbCtD
Sumatriptan—SLCO1A2—Lovastatin—atherosclerosis	0.0599	0.0797	CbGbCtD
Sumatriptan—SLCO1B1—Simvastatin—atherosclerosis	0.0577	0.0768	CbGbCtD
Sumatriptan—SLCO1B1—Lovastatin—atherosclerosis	0.0565	0.0751	CbGbCtD
Sumatriptan—SLCO1B1—Pravastatin—atherosclerosis	0.0565	0.0751	CbGbCtD
Sumatriptan—ABCG2—Rosuvastatin—atherosclerosis	0.0493	0.0656	CbGbCtD
Sumatriptan—ABCG2—Ezetimibe—atherosclerosis	0.0493	0.0656	CbGbCtD
Sumatriptan—ABCG2—Pravastatin—atherosclerosis	0.0449	0.0597	CbGbCtD
Sumatriptan—ABCB1—Ezetimibe—atherosclerosis	0.0178	0.0237	CbGbCtD
Sumatriptan—ABCB1—Simvastatin—atherosclerosis	0.0165	0.022	CbGbCtD
Sumatriptan—ABCB1—Lovastatin—atherosclerosis	0.0162	0.0215	CbGbCtD
Sumatriptan—ABCB1—Pravastatin—atherosclerosis	0.0162	0.0215	CbGbCtD
Sumatriptan—Melatonin—MPO—atherosclerosis	0.000633	0.571	CrCbGaD
Sumatriptan—Melatonin—ESR1—atherosclerosis	0.000475	0.429	CrCbGaD
Sumatriptan—Haemorrhage—Niacin—atherosclerosis	0.000314	0.00195	CcSEcCtD
Sumatriptan—Flatulence—Lovastatin—atherosclerosis	0.000313	0.00194	CcSEcCtD
Sumatriptan—Hypoaesthesia—Niacin—atherosclerosis	0.000312	0.00194	CcSEcCtD
Sumatriptan—Erythema—Ezetimibe—atherosclerosis	0.000312	0.00193	CcSEcCtD
Sumatriptan—Dysgeusia—Lovastatin—atherosclerosis	0.000312	0.00193	CcSEcCtD
Sumatriptan—Confusional state—Rosuvastatin—atherosclerosis	0.000309	0.00192	CcSEcCtD
Sumatriptan—Back pain—Lovastatin—atherosclerosis	0.000308	0.00191	CcSEcCtD
Sumatriptan—Hypoaesthesia—Pravastatin—atherosclerosis	0.000307	0.00191	CcSEcCtD
Sumatriptan—Flatulence—Ezetimibe—atherosclerosis	0.000307	0.00191	CcSEcCtD
Sumatriptan—Chills—Simvastatin—atherosclerosis	0.000307	0.0019	CcSEcCtD
Sumatriptan—Muscle spasms—Lovastatin—atherosclerosis	0.000306	0.0019	CcSEcCtD
Sumatriptan—Infection—Rosuvastatin—atherosclerosis	0.000304	0.00189	CcSEcCtD
Sumatriptan—Visual impairment—Niacin—atherosclerosis	0.000302	0.00188	CcSEcCtD
Sumatriptan—Back pain—Ezetimibe—atherosclerosis	0.000302	0.00187	CcSEcCtD
Sumatriptan—Nervous system disorder—Rosuvastatin—atherosclerosis	0.0003	0.00186	CcSEcCtD
Sumatriptan—Muscle spasms—Ezetimibe—atherosclerosis	0.0003	0.00186	CcSEcCtD
Sumatriptan—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.0003	0.00186	CcSEcCtD
Sumatriptan—Tremor—Lovastatin—atherosclerosis	0.000298	0.00185	CcSEcCtD
Sumatriptan—Visual impairment—Pravastatin—atherosclerosis	0.000298	0.00185	CcSEcCtD
Sumatriptan—Erythema—Simvastatin—atherosclerosis	0.000298	0.00185	CcSEcCtD
Sumatriptan—Ill-defined disorder—Lovastatin—atherosclerosis	0.000295	0.00183	CcSEcCtD
Sumatriptan—Eye disorder—Niacin—atherosclerosis	0.000293	0.00182	CcSEcCtD
Sumatriptan—Flatulence—Simvastatin—atherosclerosis	0.000293	0.00182	CcSEcCtD
Sumatriptan—Tinnitus—Niacin—atherosclerosis	0.000293	0.00181	CcSEcCtD
Sumatriptan—Dysgeusia—Simvastatin—atherosclerosis	0.000291	0.00181	CcSEcCtD
Sumatriptan—Flushing—Niacin—atherosclerosis	0.000291	0.00181	CcSEcCtD
Sumatriptan—Angioedema—Lovastatin—atherosclerosis	0.000291	0.0018	CcSEcCtD
Sumatriptan—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000289	0.0018	CcSEcCtD
Sumatriptan—Anaemia—Ezetimibe—atherosclerosis	0.000288	0.00179	CcSEcCtD
Sumatriptan—Tinnitus—Pravastatin—atherosclerosis	0.000288	0.00179	CcSEcCtD
Sumatriptan—Malaise—Lovastatin—atherosclerosis	0.000287	0.00178	CcSEcCtD
Sumatriptan—Flushing—Pravastatin—atherosclerosis	0.000287	0.00178	CcSEcCtD
Sumatriptan—Muscle spasms—Simvastatin—atherosclerosis	0.000286	0.00177	CcSEcCtD
Sumatriptan—Vertigo—Lovastatin—atherosclerosis	0.000286	0.00177	CcSEcCtD
Sumatriptan—Angioedema—Ezetimibe—atherosclerosis	0.000285	0.00177	CcSEcCtD
Sumatriptan—Angiopathy—Niacin—atherosclerosis	0.000285	0.00177	CcSEcCtD
Sumatriptan—Chills—Niacin—atherosclerosis	0.000282	0.00175	CcSEcCtD
Sumatriptan—Malaise—Ezetimibe—atherosclerosis	0.000281	0.00174	CcSEcCtD
Sumatriptan—Arrhythmia—Niacin—atherosclerosis	0.00028	0.00174	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000279	0.00173	CcSEcCtD
Sumatriptan—Tremor—Simvastatin—atherosclerosis	0.000279	0.00173	CcSEcCtD
Sumatriptan—Chills—Pravastatin—atherosclerosis	0.000277	0.00172	CcSEcCtD
Sumatriptan—Ill-defined disorder—Simvastatin—atherosclerosis	0.000276	0.00171	CcSEcCtD
Sumatriptan—Arrhythmia—Pravastatin—atherosclerosis	0.000276	0.00171	CcSEcCtD
Sumatriptan—Palpitations—Ezetimibe—atherosclerosis	0.000276	0.00171	CcSEcCtD
Sumatriptan—Paraesthesia—Rosuvastatin—atherosclerosis	0.000275	0.00171	CcSEcCtD
Sumatriptan—Anaemia—Simvastatin—atherosclerosis	0.000275	0.00171	CcSEcCtD
Sumatriptan—Erythema—Niacin—atherosclerosis	0.000273	0.00169	CcSEcCtD
Sumatriptan—Cough—Ezetimibe—atherosclerosis	0.000272	0.00169	CcSEcCtD
Sumatriptan—Angioedema—Simvastatin—atherosclerosis	0.000272	0.00169	CcSEcCtD
Sumatriptan—Chest pain—Lovastatin—atherosclerosis	0.000271	0.00168	CcSEcCtD
Sumatriptan—Arthralgia—Lovastatin—atherosclerosis	0.000271	0.00168	CcSEcCtD
Sumatriptan—Myalgia—Lovastatin—atherosclerosis	0.000271	0.00168	CcSEcCtD
Sumatriptan—Anxiety—Lovastatin—atherosclerosis	0.00027	0.00167	CcSEcCtD
Sumatriptan—Hypertension—Ezetimibe—atherosclerosis	0.000269	0.00167	CcSEcCtD
Sumatriptan—Flatulence—Niacin—atherosclerosis	0.000269	0.00167	CcSEcCtD
Sumatriptan—Malaise—Simvastatin—atherosclerosis	0.000268	0.00166	CcSEcCtD
Sumatriptan—Discomfort—Lovastatin—atherosclerosis	0.000268	0.00166	CcSEcCtD
Sumatriptan—Vertigo—Simvastatin—atherosclerosis	0.000267	0.00166	CcSEcCtD
Sumatriptan—Arthralgia—Ezetimibe—atherosclerosis	0.000266	0.00165	CcSEcCtD
Sumatriptan—Chest pain—Ezetimibe—atherosclerosis	0.000266	0.00165	CcSEcCtD
Sumatriptan—Myalgia—Ezetimibe—atherosclerosis	0.000266	0.00165	CcSEcCtD
Sumatriptan—Flatulence—Pravastatin—atherosclerosis	0.000265	0.00164	CcSEcCtD
Sumatriptan—Dry mouth—Lovastatin—atherosclerosis	0.000265	0.00164	CcSEcCtD
Sumatriptan—Dysgeusia—Pravastatin—atherosclerosis	0.000263	0.00163	CcSEcCtD
Sumatriptan—Muscle spasms—Niacin—atherosclerosis	0.000263	0.00163	CcSEcCtD
Sumatriptan—Discomfort—Ezetimibe—atherosclerosis	0.000262	0.00163	CcSEcCtD
Sumatriptan—Pain—Rosuvastatin—atherosclerosis	0.000262	0.00162	CcSEcCtD
Sumatriptan—Constipation—Rosuvastatin—atherosclerosis	0.000262	0.00162	CcSEcCtD
Sumatriptan—Confusional state—Lovastatin—atherosclerosis	0.000262	0.00162	CcSEcCtD
Sumatriptan—Dry mouth—Ezetimibe—atherosclerosis	0.00026	0.00161	CcSEcCtD
Sumatriptan—Anaphylactic shock—Lovastatin—atherosclerosis	0.00026	0.00161	CcSEcCtD
Sumatriptan—Muscle spasms—Pravastatin—atherosclerosis	0.000259	0.0016	CcSEcCtD
Sumatriptan—Infection—Lovastatin—atherosclerosis	0.000258	0.0016	CcSEcCtD
Sumatriptan—Confusional state—Ezetimibe—atherosclerosis	0.000257	0.00159	CcSEcCtD
Sumatriptan—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000255	0.00158	CcSEcCtD
Sumatriptan—Thrombocytopenia—Lovastatin—atherosclerosis	0.000254	0.00158	CcSEcCtD
Sumatriptan—Myalgia—Simvastatin—atherosclerosis	0.000253	0.00157	CcSEcCtD
Sumatriptan—Arthralgia—Simvastatin—atherosclerosis	0.000253	0.00157	CcSEcCtD
Sumatriptan—Chest pain—Simvastatin—atherosclerosis	0.000253	0.00157	CcSEcCtD
Sumatriptan—Infection—Ezetimibe—atherosclerosis	0.000253	0.00157	CcSEcCtD
Sumatriptan—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000252	0.00157	CcSEcCtD
Sumatriptan—Anxiety—Simvastatin—atherosclerosis	0.000252	0.00157	CcSEcCtD
Sumatriptan—Tremor—Pravastatin—atherosclerosis	0.000252	0.00156	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000251	0.00155	CcSEcCtD
Sumatriptan—Discomfort—Simvastatin—atherosclerosis	0.00025	0.00155	CcSEcCtD
Sumatriptan—Nervous system disorder—Ezetimibe—atherosclerosis	0.00025	0.00155	CcSEcCtD
Sumatriptan—Angioedema—Niacin—atherosclerosis	0.00025	0.00155	CcSEcCtD
Sumatriptan—Ill-defined disorder—Pravastatin—atherosclerosis	0.00025	0.00155	CcSEcCtD
Sumatriptan—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000249	0.00155	CcSEcCtD
Sumatriptan—Anaemia—Pravastatin—atherosclerosis	0.000249	0.00154	CcSEcCtD
Sumatriptan—Skin disorder—Ezetimibe—atherosclerosis	0.000247	0.00153	CcSEcCtD
Sumatriptan—Angioedema—Pravastatin—atherosclerosis	0.000246	0.00152	CcSEcCtD
Sumatriptan—Vertigo—Niacin—atherosclerosis	0.000245	0.00152	CcSEcCtD
Sumatriptan—Syncope—Niacin—atherosclerosis	0.000245	0.00152	CcSEcCtD
Sumatriptan—Confusional state—Simvastatin—atherosclerosis	0.000245	0.00152	CcSEcCtD
Sumatriptan—Urticaria—Rosuvastatin—atherosclerosis	0.000243	0.00151	CcSEcCtD
Sumatriptan—Anaphylactic shock—Simvastatin—atherosclerosis	0.000243	0.00151	CcSEcCtD
Sumatriptan—Oedema—Simvastatin—atherosclerosis	0.000243	0.00151	CcSEcCtD
Sumatriptan—Malaise—Pravastatin—atherosclerosis	0.000243	0.0015	CcSEcCtD
Sumatriptan—Abdominal pain—Rosuvastatin—atherosclerosis	0.000242	0.0015	CcSEcCtD
Sumatriptan—Vertigo—Pravastatin—atherosclerosis	0.000242	0.0015	CcSEcCtD
Sumatriptan—Palpitations—Niacin—atherosclerosis	0.000241	0.0015	CcSEcCtD
Sumatriptan—Infection—Simvastatin—atherosclerosis	0.000241	0.0015	CcSEcCtD
Sumatriptan—Loss of consciousness—Niacin—atherosclerosis	0.00024	0.00149	CcSEcCtD
Sumatriptan—Cough—Niacin—atherosclerosis	0.000238	0.00148	CcSEcCtD
Sumatriptan—Thrombocytopenia—Simvastatin—atherosclerosis	0.000238	0.00147	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000237	0.00147	CcSEcCtD
Sumatriptan—Cough—Pravastatin—atherosclerosis	0.000235	0.00146	CcSEcCtD
Sumatriptan—Paraesthesia—Lovastatin—atherosclerosis	0.000233	0.00145	CcSEcCtD
Sumatriptan—Arthralgia—Niacin—atherosclerosis	0.000233	0.00144	CcSEcCtD
Sumatriptan—Myalgia—Niacin—atherosclerosis	0.000233	0.00144	CcSEcCtD
Sumatriptan—Hypertension—Pravastatin—atherosclerosis	0.000232	0.00144	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000232	0.00144	CcSEcCtD
Sumatriptan—Dyspnoea—Lovastatin—atherosclerosis	0.000231	0.00144	CcSEcCtD
Sumatriptan—Chest pain—Pravastatin—atherosclerosis	0.000229	0.00142	CcSEcCtD
Sumatriptan—Arthralgia—Pravastatin—atherosclerosis	0.000229	0.00142	CcSEcCtD
Sumatriptan—Myalgia—Pravastatin—atherosclerosis	0.000229	0.00142	CcSEcCtD
Sumatriptan—Paraesthesia—Ezetimibe—atherosclerosis	0.000229	0.00142	CcSEcCtD
Sumatriptan—Anxiety—Pravastatin—atherosclerosis	0.000228	0.00142	CcSEcCtD
Sumatriptan—Dry mouth—Niacin—atherosclerosis	0.000227	0.00141	CcSEcCtD
Sumatriptan—Dyspnoea—Ezetimibe—atherosclerosis	0.000227	0.00141	CcSEcCtD
Sumatriptan—Discomfort—Pravastatin—atherosclerosis	0.000226	0.0014	CcSEcCtD
Sumatriptan—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000226	0.0014	CcSEcCtD
Sumatriptan—Decreased appetite—Lovastatin—atherosclerosis	0.000226	0.0014	CcSEcCtD
Sumatriptan—Fatigue—Lovastatin—atherosclerosis	0.000224	0.00139	CcSEcCtD
Sumatriptan—Anaphylactic shock—Niacin—atherosclerosis	0.000223	0.00138	CcSEcCtD
Sumatriptan—Oedema—Niacin—atherosclerosis	0.000223	0.00138	CcSEcCtD
Sumatriptan—Constipation—Lovastatin—atherosclerosis	0.000222	0.00138	CcSEcCtD
Sumatriptan—Pain—Lovastatin—atherosclerosis	0.000222	0.00138	CcSEcCtD
Sumatriptan—Confusional state—Pravastatin—atherosclerosis	0.000221	0.00137	CcSEcCtD
Sumatriptan—Decreased appetite—Ezetimibe—atherosclerosis	0.000221	0.00137	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000221	0.00137	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00022	0.00136	CcSEcCtD
Sumatriptan—Asthenia—Rosuvastatin—atherosclerosis	0.00022	0.00136	CcSEcCtD
Sumatriptan—Anaphylactic shock—Pravastatin—atherosclerosis	0.00022	0.00136	CcSEcCtD
Sumatriptan—Oedema—Pravastatin—atherosclerosis	0.00022	0.00136	CcSEcCtD
Sumatriptan—Fatigue—Ezetimibe—atherosclerosis	0.00022	0.00136	CcSEcCtD
Sumatriptan—Shock—Niacin—atherosclerosis	0.000219	0.00136	CcSEcCtD
Sumatriptan—Infection—Pravastatin—atherosclerosis	0.000218	0.00135	CcSEcCtD
Sumatriptan—Paraesthesia—Simvastatin—atherosclerosis	0.000218	0.00135	CcSEcCtD
Sumatriptan—Pain—Ezetimibe—atherosclerosis	0.000218	0.00135	CcSEcCtD
Sumatriptan—Constipation—Ezetimibe—atherosclerosis	0.000218	0.00135	CcSEcCtD
Sumatriptan—Tachycardia—Niacin—atherosclerosis	0.000218	0.00135	CcSEcCtD
Sumatriptan—Pruritus—Rosuvastatin—atherosclerosis	0.000217	0.00134	CcSEcCtD
Sumatriptan—Skin disorder—Niacin—atherosclerosis	0.000217	0.00134	CcSEcCtD
Sumatriptan—Dyspnoea—Simvastatin—atherosclerosis	0.000216	0.00134	CcSEcCtD
Sumatriptan—Hyperhidrosis—Niacin—atherosclerosis	0.000216	0.00134	CcSEcCtD
Sumatriptan—Thrombocytopenia—Pravastatin—atherosclerosis	0.000215	0.00133	CcSEcCtD
Sumatriptan—Feeling abnormal—Lovastatin—atherosclerosis	0.000214	0.00133	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000212	0.00132	CcSEcCtD
Sumatriptan—Hyperhidrosis—Pravastatin—atherosclerosis	0.000212	0.00132	CcSEcCtD
Sumatriptan—Decreased appetite—Simvastatin—atherosclerosis	0.000211	0.00131	CcSEcCtD
Sumatriptan—Feeling abnormal—Ezetimibe—atherosclerosis	0.00021	0.0013	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00021	0.0013	CcSEcCtD
Sumatriptan—Diarrhoea—Rosuvastatin—atherosclerosis	0.00021	0.0013	CcSEcCtD
Sumatriptan—Fatigue—Simvastatin—atherosclerosis	0.000209	0.0013	CcSEcCtD
Sumatriptan—Hypotension—Niacin—atherosclerosis	0.000208	0.00129	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000208	0.00129	CcSEcCtD
Sumatriptan—Pain—Simvastatin—atherosclerosis	0.000208	0.00129	CcSEcCtD
Sumatriptan—Constipation—Simvastatin—atherosclerosis	0.000208	0.00129	CcSEcCtD
Sumatriptan—Urticaria—Lovastatin—atherosclerosis	0.000206	0.00128	CcSEcCtD
Sumatriptan—Abdominal pain—Lovastatin—atherosclerosis	0.000205	0.00127	CcSEcCtD
Sumatriptan—Body temperature increased—Lovastatin—atherosclerosis	0.000205	0.00127	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000203	0.00126	CcSEcCtD
Sumatriptan—Dizziness—Rosuvastatin—atherosclerosis	0.000203	0.00126	CcSEcCtD
Sumatriptan—Urticaria—Ezetimibe—atherosclerosis	0.000202	0.00125	CcSEcCtD
Sumatriptan—Abdominal pain—Ezetimibe—atherosclerosis	0.000201	0.00125	CcSEcCtD
Sumatriptan—Body temperature increased—Ezetimibe—atherosclerosis	0.000201	0.00125	CcSEcCtD
Sumatriptan—Paraesthesia—Niacin—atherosclerosis	0.0002	0.00124	CcSEcCtD
Sumatriptan—Feeling abnormal—Simvastatin—atherosclerosis	0.0002	0.00124	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.0002	0.00124	CcSEcCtD
Sumatriptan—Dyspnoea—Niacin—atherosclerosis	0.000199	0.00123	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000199	0.00123	CcSEcCtD
Sumatriptan—Somnolence—Niacin—atherosclerosis	0.000198	0.00123	CcSEcCtD
Sumatriptan—Paraesthesia—Pravastatin—atherosclerosis	0.000197	0.00122	CcSEcCtD
Sumatriptan—Dyspnoea—Pravastatin—atherosclerosis	0.000196	0.00121	CcSEcCtD
Sumatriptan—Decreased appetite—Niacin—atherosclerosis	0.000194	0.0012	CcSEcCtD
Sumatriptan—Rash—Rosuvastatin—atherosclerosis	0.000193	0.0012	CcSEcCtD
Sumatriptan—Dermatitis—Rosuvastatin—atherosclerosis	0.000193	0.0012	CcSEcCtD
Sumatriptan—Urticaria—Simvastatin—atherosclerosis	0.000193	0.0012	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Niacin—atherosclerosis	0.000193	0.00119	CcSEcCtD
Sumatriptan—Abdominal pain—Simvastatin—atherosclerosis	0.000192	0.00119	CcSEcCtD
Sumatriptan—Body temperature increased—Simvastatin—atherosclerosis	0.000192	0.00119	CcSEcCtD
Sumatriptan—Headache—Rosuvastatin—atherosclerosis	0.000192	0.00119	CcSEcCtD
Sumatriptan—Hypersensitivity—Lovastatin—atherosclerosis	0.000191	0.00119	CcSEcCtD
Sumatriptan—Decreased appetite—Pravastatin—atherosclerosis	0.000191	0.00118	CcSEcCtD
Sumatriptan—Pain—Niacin—atherosclerosis	0.000191	0.00118	CcSEcCtD
Sumatriptan—Fatigue—Pravastatin—atherosclerosis	0.000189	0.00117	CcSEcCtD
Sumatriptan—Pain—Pravastatin—atherosclerosis	0.000188	0.00116	CcSEcCtD
Sumatriptan—Constipation—Pravastatin—atherosclerosis	0.000188	0.00116	CcSEcCtD
Sumatriptan—Hypersensitivity—Ezetimibe—atherosclerosis	0.000188	0.00116	CcSEcCtD
Sumatriptan—Asthenia—Lovastatin—atherosclerosis	0.000186	0.00116	CcSEcCtD
Sumatriptan—Pruritus—Lovastatin—atherosclerosis	0.000184	0.00114	CcSEcCtD
Sumatriptan—Asthenia—Ezetimibe—atherosclerosis	0.000183	0.00113	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Niacin—atherosclerosis	0.000182	0.00113	CcSEcCtD
Sumatriptan—Nausea—Rosuvastatin—atherosclerosis	0.000182	0.00113	CcSEcCtD
Sumatriptan—Feeling abnormal—Pravastatin—atherosclerosis	0.000181	0.00112	CcSEcCtD
Sumatriptan—Pruritus—Ezetimibe—atherosclerosis	0.00018	0.00112	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00018	0.00111	CcSEcCtD
Sumatriptan—Hypersensitivity—Simvastatin—atherosclerosis	0.000179	0.00111	CcSEcCtD
Sumatriptan—Diarrhoea—Lovastatin—atherosclerosis	0.000178	0.0011	CcSEcCtD
Sumatriptan—Urticaria—Niacin—atherosclerosis	0.000177	0.0011	CcSEcCtD
Sumatriptan—Body temperature increased—Niacin—atherosclerosis	0.000176	0.00109	CcSEcCtD
Sumatriptan—Abdominal pain—Niacin—atherosclerosis	0.000176	0.00109	CcSEcCtD
Sumatriptan—Urticaria—Pravastatin—atherosclerosis	0.000174	0.00108	CcSEcCtD
Sumatriptan—Asthenia—Simvastatin—atherosclerosis	0.000174	0.00108	CcSEcCtD
Sumatriptan—Diarrhoea—Ezetimibe—atherosclerosis	0.000174	0.00108	CcSEcCtD
Sumatriptan—Abdominal pain—Pravastatin—atherosclerosis	0.000174	0.00108	CcSEcCtD
Sumatriptan—Body temperature increased—Pravastatin—atherosclerosis	0.000174	0.00108	CcSEcCtD
Sumatriptan—Pruritus—Simvastatin—atherosclerosis	0.000172	0.00107	CcSEcCtD
Sumatriptan—Dizziness—Lovastatin—atherosclerosis	0.000172	0.00106	CcSEcCtD
Sumatriptan—Dizziness—Ezetimibe—atherosclerosis	0.000168	0.00104	CcSEcCtD
Sumatriptan—Diarrhoea—Simvastatin—atherosclerosis	0.000166	0.00103	CcSEcCtD
Sumatriptan—Vomiting—Lovastatin—atherosclerosis	0.000165	0.00102	CcSEcCtD
Sumatriptan—Hypersensitivity—Niacin—atherosclerosis	0.000164	0.00102	CcSEcCtD
Sumatriptan—Rash—Lovastatin—atherosclerosis	0.000164	0.00102	CcSEcCtD
Sumatriptan—Dermatitis—Lovastatin—atherosclerosis	0.000164	0.00101	CcSEcCtD
Sumatriptan—Headache—Lovastatin—atherosclerosis	0.000163	0.00101	CcSEcCtD
Sumatriptan—Vomiting—Ezetimibe—atherosclerosis	0.000162	0.001	CcSEcCtD
Sumatriptan—Hypersensitivity—Pravastatin—atherosclerosis	0.000162	0.001	CcSEcCtD
Sumatriptan—Dizziness—Simvastatin—atherosclerosis	0.000161	0.000996	CcSEcCtD
Sumatriptan—Rash—Ezetimibe—atherosclerosis	0.000161	0.000996	CcSEcCtD
Sumatriptan—Dermatitis—Ezetimibe—atherosclerosis	0.00016	0.000995	CcSEcCtD
Sumatriptan—Asthenia—Niacin—atherosclerosis	0.00016	0.000992	CcSEcCtD
Sumatriptan—Headache—Ezetimibe—atherosclerosis	0.00016	0.000989	CcSEcCtD
Sumatriptan—Pruritus—Niacin—atherosclerosis	0.000158	0.000978	CcSEcCtD
Sumatriptan—Asthenia—Pravastatin—atherosclerosis	0.000158	0.000977	CcSEcCtD
Sumatriptan—Pruritus—Pravastatin—atherosclerosis	0.000155	0.000963	CcSEcCtD
Sumatriptan—Vomiting—Simvastatin—atherosclerosis	0.000154	0.000957	CcSEcCtD
Sumatriptan—Nausea—Lovastatin—atherosclerosis	0.000154	0.000956	CcSEcCtD
Sumatriptan—Rash—Simvastatin—atherosclerosis	0.000153	0.000949	CcSEcCtD
Sumatriptan—Dermatitis—Simvastatin—atherosclerosis	0.000153	0.000949	CcSEcCtD
Sumatriptan—Diarrhoea—Niacin—atherosclerosis	0.000153	0.000946	CcSEcCtD
Sumatriptan—Headache—Simvastatin—atherosclerosis	0.000152	0.000943	CcSEcCtD
Sumatriptan—Nausea—Ezetimibe—atherosclerosis	0.000151	0.000938	CcSEcCtD
Sumatriptan—Diarrhoea—Pravastatin—atherosclerosis	0.00015	0.000932	CcSEcCtD
Sumatriptan—Dizziness—Niacin—atherosclerosis	0.000147	0.000914	CcSEcCtD
Sumatriptan—Dizziness—Pravastatin—atherosclerosis	0.000145	0.0009	CcSEcCtD
Sumatriptan—Nausea—Simvastatin—atherosclerosis	0.000144	0.000894	CcSEcCtD
Sumatriptan—Vomiting—Niacin—atherosclerosis	0.000142	0.000879	CcSEcCtD
Sumatriptan—Rash—Niacin—atherosclerosis	0.000141	0.000872	CcSEcCtD
Sumatriptan—Dermatitis—Niacin—atherosclerosis	0.00014	0.000871	CcSEcCtD
Sumatriptan—Headache—Niacin—atherosclerosis	0.00014	0.000866	CcSEcCtD
Sumatriptan—Vomiting—Pravastatin—atherosclerosis	0.00014	0.000866	CcSEcCtD
Sumatriptan—Rash—Pravastatin—atherosclerosis	0.000138	0.000858	CcSEcCtD
Sumatriptan—Dermatitis—Pravastatin—atherosclerosis	0.000138	0.000858	CcSEcCtD
Sumatriptan—Headache—Pravastatin—atherosclerosis	0.000138	0.000853	CcSEcCtD
Sumatriptan—Nausea—Niacin—atherosclerosis	0.000132	0.000821	CcSEcCtD
Sumatriptan—Nausea—Pravastatin—atherosclerosis	0.00013	0.000809	CcSEcCtD
Sumatriptan—SLCO1A2—Metabolism—APOA1—atherosclerosis	1.21e-05	0.000141	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—EDNRA—atherosclerosis	1.21e-05	0.000141	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCR2—atherosclerosis	1.21e-05	0.000141	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CYBA—atherosclerosis	1.2e-05	0.000141	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—SPP1—atherosclerosis	1.2e-05	0.00014	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PPARA—atherosclerosis	1.2e-05	0.00014	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—PIK3CG—atherosclerosis	1.19e-05	0.000139	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CXCL8—atherosclerosis	1.19e-05	0.000139	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.19e-05	0.000139	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—CD36—atherosclerosis	1.19e-05	0.000139	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.18e-05	0.000138	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—GSTM1—atherosclerosis	1.18e-05	0.000138	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—GHRL—atherosclerosis	1.18e-05	0.000138	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PARP1—atherosclerosis	1.18e-05	0.000138	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PLAT—atherosclerosis	1.18e-05	0.000138	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—KNG1—atherosclerosis	1.18e-05	0.000138	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—AGTR1—atherosclerosis	1.17e-05	0.000137	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—AGT—atherosclerosis	1.16e-05	0.000135	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—LPL—atherosclerosis	1.16e-05	0.000135	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ALOX5—atherosclerosis	1.15e-05	0.000134	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CCL2—atherosclerosis	1.15e-05	0.000134	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PLG—atherosclerosis	1.14e-05	0.000133	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—APOE—atherosclerosis	1.14e-05	0.000133	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PDGFB—atherosclerosis	1.13e-05	0.000132	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—F2—atherosclerosis	1.13e-05	0.000132	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—GPX1—atherosclerosis	1.13e-05	0.000132	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—MTHFR—atherosclerosis	1.13e-05	0.000131	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—CAV1—atherosclerosis	1.12e-05	0.000131	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CXCL8—atherosclerosis	1.12e-05	0.000131	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—APOA1—atherosclerosis	1.12e-05	0.000131	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PDGFB—atherosclerosis	1.11e-05	0.000129	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.11e-05	0.000129	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PIK3CG—atherosclerosis	1.11e-05	0.000129	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—AGT—atherosclerosis	1.1e-05	0.000129	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PPARA—atherosclerosis	1.1e-05	0.000129	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—CD36—atherosclerosis	1.1e-05	0.000128	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—AKT1—atherosclerosis	1.09e-05	0.000127	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—PIK3CG—atherosclerosis	1.08e-05	0.000126	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—LEP—atherosclerosis	1.08e-05	0.000126	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—APOE—atherosclerosis	1.08e-05	0.000126	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—AGT—atherosclerosis	1.08e-05	0.000126	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—SOCS3—atherosclerosis	1.08e-05	0.000126	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CAV1—atherosclerosis	1.07e-05	0.000125	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—APOA1—atherosclerosis	1.07e-05	0.000125	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—AGT—atherosclerosis	1.07e-05	0.000125	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—IL6—atherosclerosis	1.07e-05	0.000125	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PPARG—atherosclerosis	1.07e-05	0.000125	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—LEP—atherosclerosis	1.06e-05	0.000124	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—APOE—atherosclerosis	1.06e-05	0.000124	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CAV1—atherosclerosis	1.05e-05	0.000123	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—APOE—atherosclerosis	1.05e-05	0.000122	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—APOA1—atherosclerosis	1.05e-05	0.000122	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—INS—atherosclerosis	1.05e-05	0.000122	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MMP3—atherosclerosis	1.04e-05	0.000122	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—MTHFR—atherosclerosis	1.04e-05	0.000122	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IGF2—atherosclerosis	1.04e-05	0.000121	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—CAV1—atherosclerosis	1.04e-05	0.000121	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—APOA1—atherosclerosis	1.04e-05	0.000121	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—KNG1—atherosclerosis	1.03e-05	0.000121	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—ESR1—atherosclerosis	1.03e-05	0.000121	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—NAMPT—atherosclerosis	1.03e-05	0.000121	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—AGTR1—atherosclerosis	1.03e-05	0.00012	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—LIPC—atherosclerosis	1.03e-05	0.00012	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PIK3CG—atherosclerosis	1.02e-05	0.00012	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PPARA—atherosclerosis	1.02e-05	0.000119	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—F2—atherosclerosis	1.02e-05	0.000119	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—APOC3—atherosclerosis	1.02e-05	0.000119	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MMP9—atherosclerosis	1.02e-05	0.000119	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—LDLR—atherosclerosis	1.01e-05	0.000118	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—ESR1—atherosclerosis	1.01e-05	0.000118	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—APOB—atherosclerosis	1.01e-05	0.000118	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CCL2—atherosclerosis	1.01e-05	0.000118	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—NFKB1—atherosclerosis	1.01e-05	0.000118	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PLG—atherosclerosis	1e-05	0.000117	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—CXCL8—atherosclerosis	1e-05	0.000117	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—F2—atherosclerosis	9.99e-06	0.000117	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—EDN1—atherosclerosis	9.92e-06	0.000116	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—AGT—atherosclerosis	9.9e-06	0.000116	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CETP—atherosclerosis	9.89e-06	0.000116	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MAPK8—atherosclerosis	9.89e-06	0.000116	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PPARG—atherosclerosis	9.89e-06	0.000115	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—AKT1—atherosclerosis	9.86e-06	0.000115	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCL5—atherosclerosis	9.84e-06	0.000115	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PIK3CG—atherosclerosis	9.76e-06	0.000114	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	9.71e-06	0.000113	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—APOE—atherosclerosis	9.7e-06	0.000113	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—INS—atherosclerosis	9.7e-06	0.000113	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—LPL—atherosclerosis	9.63e-06	0.000112	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—CAV1—atherosclerosis	9.61e-06	0.000112	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—ALB—atherosclerosis	9.59e-06	0.000112	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—APOA1—atherosclerosis	9.59e-06	0.000112	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PIK3CG—atherosclerosis	9.56e-06	0.000112	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—SOCS3—atherosclerosis	9.48e-06	0.000111	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—SCARB1—atherosclerosis	9.47e-06	0.000111	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PIK3CG—atherosclerosis	9.45e-06	0.00011	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PRKCG—atherosclerosis	9.36e-06	0.000109	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—MAPK3—atherosclerosis	9.35e-06	0.000109	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—INS—atherosclerosis	9.24e-06	0.000108	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—NOS3—atherosclerosis	9.18e-06	0.000107	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MMP3—atherosclerosis	9.16e-06	0.000107	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—MAPK3—atherosclerosis	9.15e-06	0.000107	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—VEGFA—atherosclerosis	9.13e-06	0.000107	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PPARG—atherosclerosis	9.13e-06	0.000107	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IGF2—atherosclerosis	9.12e-06	0.000107	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—SPP1—atherosclerosis	9.12e-06	0.000106	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCL2—atherosclerosis	9.09e-06	0.000106	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—CXCL8—atherosclerosis	9.08e-06	0.000106	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—INS—atherosclerosis	9.05e-06	0.000106	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—STAT3—atherosclerosis	9.04e-06	0.000106	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—INS—atherosclerosis	8.95e-06	0.000105	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—HMGCR—atherosclerosis	8.95e-06	0.000104	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—IGF1—atherosclerosis	8.94e-06	0.000104	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCL2—atherosclerosis	8.9e-06	0.000104	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—ALB—atherosclerosis	8.89e-06	0.000104	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—APOB—atherosclerosis	8.85e-06	0.000103	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	8.78e-06	0.000103	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	8.77e-06	0.000102	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PIK3CG—atherosclerosis	8.75e-06	0.000102	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—IGF1—atherosclerosis	8.75e-06	0.000102	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—EDN1—atherosclerosis	8.71e-06	0.000102	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCL5—atherosclerosis	8.64e-06	0.000101	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MAPK3—atherosclerosis	8.64e-06	0.000101	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—NOS3—atherosclerosis	8.5e-06	9.93e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—SERPINE1—atherosclerosis	8.49e-06	9.92e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—LPL—atherosclerosis	8.45e-06	9.87e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PPARG—atherosclerosis	8.45e-06	9.87e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	8.44e-06	9.85e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PTGS2—atherosclerosis	8.39e-06	9.81e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—TGFB1—atherosclerosis	8.38e-06	9.79e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	8.31e-06	9.71e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—INS—atherosclerosis	8.29e-06	9.68e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—AGT—atherosclerosis	8.24e-06	9.62e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PRKCG—atherosclerosis	8.22e-06	9.6e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—ALB—atherosclerosis	8.21e-06	9.58e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NOS3—atherosclerosis	8.1e-06	9.47e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—LEP—atherosclerosis	8.07e-06	9.43e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—APOE—atherosclerosis	8.07e-06	9.43e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—SPP1—atherosclerosis	8e-06	9.35e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CAV1—atherosclerosis	7.99e-06	9.34e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—APOA1—atherosclerosis	7.98e-06	9.32e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ABCA1—atherosclerosis	7.97e-06	9.31e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	7.97e-06	9.31e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NOS3—atherosclerosis	7.94e-06	9.27e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—NOS3—atherosclerosis	7.85e-06	9.17e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PTGS2—atherosclerosis	7.78e-06	9.09e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—ESR1—atherosclerosis	7.7e-06	9e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—F2—atherosclerosis	7.61e-06	8.89e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ALB—atherosclerosis	7.6e-06	8.87e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PDGFB—atherosclerosis	7.41e-06	8.65e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	7.28e-06	8.51e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—NOS3—atherosclerosis	7.27e-06	8.49e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—AGT—atherosclerosis	7.23e-06	8.45e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	7.19e-06	8.4e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PTGS2—atherosclerosis	7.18e-06	8.39e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—APOE—atherosclerosis	7.08e-06	8.28e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—LEP—atherosclerosis	7.08e-06	8.28e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	7.04e-06	8.22e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CAV1—atherosclerosis	7.02e-06	8.2e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—APOA1—atherosclerosis	7e-06	8.18e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	6.97e-06	8.15e-05	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	6.94e-06	8.11e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—INS—atherosclerosis	6.89e-06	8.05e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—HMOX1—atherosclerosis	6.84e-06	7.99e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—IL6—atherosclerosis	6.84e-06	7.98e-05	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	6.8e-06	7.94e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCL2—atherosclerosis	6.78e-06	7.92e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ESR1—atherosclerosis	6.76e-06	7.9e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—IL6—atherosclerosis	6.69e-06	7.82e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—F2—atherosclerosis	6.68e-06	7.8e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IGF1—atherosclerosis	6.67e-06	7.79e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PTGS2—atherosclerosis	6.65e-06	7.76e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—APOB—atherosclerosis	6.55e-06	7.65e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MMP9—atherosclerosis	6.5e-06	7.6e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	6.43e-06	7.51e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	6.39e-06	7.47e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GSTM1—atherosclerosis	6.37e-06	7.45e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MMP9—atherosclerosis	6.37e-06	7.44e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	6.33e-06	7.4e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	6.32e-06	7.39e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—IL6—atherosclerosis	6.31e-06	7.38e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	6.31e-06	7.37e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	6.3e-06	7.36e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—LPL—atherosclerosis	6.26e-06	7.31e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	6.19e-06	7.23e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	6.17e-06	7.21e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	6.12e-06	7.15e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GPX1—atherosclerosis	6.1e-06	7.13e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—INS—atherosclerosis	6.05e-06	7.07e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NOS3—atherosclerosis	6.04e-06	7.06e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCL2—atherosclerosis	5.95e-06	6.96e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CD36—atherosclerosis	5.94e-06	6.94e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IGF1—atherosclerosis	5.85e-06	6.84e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	5.84e-06	6.82e-05	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—AKT1—atherosclerosis	5.83e-06	6.8e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—STAT3—atherosclerosis	5.78e-06	6.75e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	5.72e-06	6.68e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—STAT3—atherosclerosis	5.66e-06	6.61e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—MTHFR—atherosclerosis	5.63e-06	6.58e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	5.56e-06	6.49e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PPARA—atherosclerosis	5.53e-06	6.46e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	5.52e-06	6.45e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	5.41e-06	6.32e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	5.36e-06	6.26e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	5.36e-06	6.26e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—AGT—atherosclerosis	5.35e-06	6.25e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NOS3—atherosclerosis	5.31e-06	6.2e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	5.25e-06	6.13e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—APOE—atherosclerosis	5.24e-06	6.13e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CAV1—atherosclerosis	5.2e-06	6.07e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—APOA1—atherosclerosis	5.18e-06	6.06e-05	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	5.18e-06	6.05e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—IL6—atherosclerosis	5.1e-06	5.96e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MMP9—atherosclerosis	4.85e-06	5.67e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	4.8e-06	5.61e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.73e-06	5.53e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	4.72e-06	5.51e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CXCL8—atherosclerosis	4.71e-06	5.5e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	4.7e-06	5.49e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PPARG—atherosclerosis	4.57e-06	5.34e-05	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	4.55e-06	5.31e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—INS—atherosclerosis	4.48e-06	5.23e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—IL6—atherosclerosis	4.48e-06	5.23e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	4.36e-06	5.09e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—STAT3—atherosclerosis	4.31e-06	5.04e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MMP9—atherosclerosis	4.26e-06	4.97e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—AKT1—atherosclerosis	4.22e-06	4.93e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NFKB1—atherosclerosis	4.21e-06	4.92e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MAPK8—atherosclerosis	4.14e-06	4.84e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—AKT1—atherosclerosis	4.13e-06	4.82e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	4.12e-06	4.81e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ALB—atherosclerosis	4.11e-06	4.8e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—IL6—atherosclerosis	4.04e-06	4.72e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	4e-06	4.67e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—IL6—atherosclerosis	3.95e-06	4.62e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—NOS3—atherosclerosis	3.93e-06	4.59e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—AKT1—atherosclerosis	3.91e-06	4.57e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—VEGFA—atherosclerosis	3.82e-06	4.47e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—STAT3—atherosclerosis	3.79e-06	4.42e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—AKT1—atherosclerosis	3.73e-06	4.35e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—AKT1—atherosclerosis	3.65e-06	4.26e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MAPK3—atherosclerosis	3.62e-06	4.23e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—AKT1—atherosclerosis	3.61e-06	4.21e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PTGS2—atherosclerosis	3.59e-06	4.2e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—TGFB1—atherosclerosis	3.51e-06	4.1e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—AKT1—atherosclerosis	3.34e-06	3.9e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—IL6—atherosclerosis	3.01e-06	3.52e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—AKT1—atherosclerosis	2.78e-06	3.25e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—IL6—atherosclerosis	2.64e-06	3.09e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—AKT1—atherosclerosis	2.44e-06	2.85e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—AKT1—atherosclerosis	1.81e-06	2.11e-05	CbGpPWpGaD
